

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7971240

| | |
|---|--|
| SUBMISSION TYPE: | RESUBMISSION |
| NATURE OF CONVEYANCE: | CONFIRMATORY ASSIGNMENT |
| RESUBMIT DOCUMENT ID: | 507680375 |
| CONVEYING PARTY DATA | |
| | |
| Name | Execution Date |
| FELIX CLEEMANN | 07/26/2022 |
| ULRICH HERSEL | 07/26/2022 |
| SILVIA KADEN | 11/03/2022 |
| HARALD RAU | 07/23/2022 |
| THOMAS WEGGE | 07/26/2022 |
| RECEIVING PARTY DATA | |
| Name: | ASCENDIS PHARMA A/S |
| Street Address: | TUBORG BOULEVARD 12 |
| City: | HELLERUP |
| State/Country: | DENMARK |
| Postal Code: | 2900 |
| PROPERTY NUMBERS Total: 1 | |
| | |
| Property Type | Number |
| Application Number: | 12865693 |
| CORRESPONDENCE DATA | |
| Fax Number: | (704)444-1111 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 650-838-2012 |
| Email: | raquel.west@alston.com |
| Correspondent Name: | RAQUEL WEST |
| Address Line 1: | ALSTON & BIRD LLP |
| Address Line 2: | ONE SOUTH AT THE PLAZA, STE 4000, 101 S. TRYON ST. |
| Address Line 4: | CHARLOTTE, NORTH CAROLINA 28280-4000 |
| ATTORNEY DOCKET NUMBER: | 065588/583182 |
| NAME OF SUBMITTER: | JOE LIEBESCHUETZ |
| SIGNATURE: | /JOE LIEBESCHUETZ/ |
| DATE SIGNED: | 05/24/2023 |

Total Attachments: 6

source=583182_confirmatoryassignment#page1.tif

source=583182_confirmatoryassignment#page2.tif

source=583182_confirmatoryassignment#page3.tif

source=583182_confirmatoryassignment#page4.tif

source=583182_confirmatoryassignment#page5.tif

source=583182_confirmatoryassignment#page6.tif

Confirmatory Assignment

Whereas by contract or operation of law, all right, title and interest of inventors Dr. Felix Cleemann, Dr. Ulrich Hersel, Dr. Silvia Kaden-Vagt, Dr. Harald Rau and Dr. Thomas Wegge in US Application No. 12/865,693, international filing date January 30, 2009, now US Patent 8,906,847 titled "Prodrug Comprising a Drug Linker Conjugate" (the application), has been assigned to Ascendis Pharma GmbH of Im Neuenheimer Feld 584, Heidelberg, Germany 69120;

Whereas Ascendis Pharma GmbH has assigned all its right, title and interest in the application to Ascendis Pharma A/S;

Whereas the inventors, Ascendis Pharma GmbH and Ascendis Pharma A/S intend all right, title and interest in the application now reside in Ascendis Pharma A/S of Tuborg Boulevard 12, Hellerup, Denmark 2900;

Whereas previous assignments recorded in the United States Patent and Trademark Office at Reel/Frame 025112 / 0178, Reel/Frame 046588 / 0760, Reel/Frame 046588 / 0748 may not fully and concisely set out the intended chain of title and the assignment recorded at Reel/Frame 025112 / 0178 contains an error in the address of Ascendis Pharma A/S;

Now therefore to confirm and insofar as is relevant supplement or supplant the aforementioned assignments, for good and sufficient consideration receipt of which is acknowledged by each assignor;


Inventors Dr. Felix Cleemann, Dr. Ulrich Hersel, Dr. Silvia Kaden-Vagt, Dr. Harald Rau and Dr. Thomas Wegge have assigned and by these presents do assign all their right, title and interest in the application and any invention described therein including any right to claim priority under the Paris convention, US or other law and any patent to issue therefrom, and any continuation, divisional, continuation-in-part, reissue or other application in the US or other country claiming priority thereto and any patent to issue therefrom to Ascendis Pharma GmbH;

Ascendis Pharma GmbH has assigned and by these presents does assign all its right, title and interest in the application and any invention described therein including any right to claim priority under the Paris convention, US or other law and any patent to issue therefrom, and any continuation, divisional, continuation-in-part, reissue or other application in the US or other country claiming priority thereto and any patent to issue therefrom to Ascendis Pharma A/S;

To the extent allowed by law all assignments to be effective at least as of the international filing date of the application indicated above;


The parties authorize Ascendis Pharma A/S's attorneys to correct any matters of form
desirable to give this document effect or permit its recording.

To which the parties have set their hands on the dates indicated;



Date 26.07.2022

Dr. Felix Cleemann Date



Date 26.07.2022


Dr. Ulrich Hersel Date

Date

Dr. Silvia Kaden-Vagt Date

Date


Dr. Harald Rau Date



Date 26-7-2022


Dr. Thomas Wegge Date

Ascendis Pharma GmbH



Date 25/08/2022
Signature Date
Print name LOTTE SØNDERBJERG
Position MANAGING DIRECTOR

Ascendis Pharma A/S



Date 25/08/2022
Signature Date
Print name MICHAEL WOLFE JENSEN
Position SVP, CHIEF LEGAL OFFICER

Confirmatory Assignment

Whereas by contract or operation of law, all right, title and interest of inventors Dr. Felix Cleemann, Dr. Ulrich Hersel, Dr. Silvia Kaden-Vagt, Dr. Harald Rau and Dr. Thomas Wegge in US Application No. 12/865,693, international filing date January 30, 2009, now US Patent 8,906,847 titled "Prodrug Comprising a Drug Linker Conjugate" (the application), has been assigned to Ascendis Pharma GmbH of Im Neuenheimer Feld 584, Heidelberg, Germany 69120;

Whereas Ascendis Pharma GmbH has assigned all its right, title and interest in the application to Ascendis Pharma A/S;

Whereas the inventors, Ascendis Pharma GmbH and Ascendis Pharma A/S intend all right, title and interest in the application now reside in Ascendis Pharma A/S of Tuborg Boulevard 12, Hellerup, Denmark 2900;

Whereas previous assignments recorded in the United States Patent and Trademark Office at Reel/Frame 025112 / 0178, Reel/Frame 046588 / 0760, Reel/Frame 046588 / 0748 may not fully and concisely set out the intended chain of title and the assignment recorded at Reel/Frame 025112 / 0178 contains an error in the address of Ascendis Pharma A/S;

Now therefore to confirm and insofar as is relevant supplement or supplant the aforementioned assignments, for good and sufficient consideration receipt of which is acknowledged by each assignor;

Inventors Dr. Felix Cleemann, Dr. Ulrich Hersel, Dr. Silvia Kaden-Vagt, Dr. Harald Rau and Dr. Thomas Wegge have assigned and by these presents do assign all their right, title and interest in the application and any invention described therein including any right to claim priority under the Paris convention, US or other law and any patent to issue therefrom, and any continuation, divisional, continuation-in-part, reissue or other application in the US or other country claiming priority thereto and any patent to issue therefrom to Ascendis Pharma GmbH;

Ascendis Pharma GmbH has assigned and by these presents does assign all its right, title and interest in the application and any invention described therein including any right to claim priority under the Paris convention, US or other law and any patent to issue therefrom, and any continuation, divisional, continuation-in-part, reissue or other application in the US or other country claiming priority thereto and any patent to issue therefrom to Ascendis Pharma A/S;

To the extent allowed by law all assignments to be effective at least as of the international filing date of the application indicated above;


The parties authorize Ascendis Pharma A/S's attorneys to correct any matters of form desirable to give this document effect or permit its recording.

To which the parties have set their hands on the dates indicated;

Dr. Felix Cleemann Date

Dr. Ulrich Hersel Date

Dr. Silvia Kaden-Vagt Date



Dr. Harald Rau Date 23 July 2022

Dr. Thomas Wegge Date

Ascendis Pharma GmbH

Signature Date
Print name _____
Position _____

Ascendis Pharma A/S

Signature Date
Print name _____
Position _____

Assignment of 12/865,693,
US 8,906,847

Confirmatory Assignment

Whereas by contract or operation of law, all right, title and interest of inventors Dr. Felix Cleemann, Dr. Ulrich Hersel, Dr. Silvia Kaden-Vagt, Dr. Harald Rau and Dr. Thomas Wegge in US Application No. 12/865,693, international filing date January 30, 2009, now US Patent 8,906,847 titled "Prodrug Comprising a Drug Linker Conjugate" (the application), has been assigned to Ascendis Pharma GmbH of Im Neuenheimer Feld 584, Heidelberg, Germany 69120;

Whereas Ascendis Pharma GmbH has assigned all its right, title and interest in the application to Ascendis Pharma A/S;

Whereas the inventors, Ascendis Pharma GmbH and Ascendis Pharma A/S intend all right, title and interest in the application now reside in Ascendis Pharma A/S of Tuborg Boulevard 12, Hellerup, Denmark 2900;

Whereas previous assignments recorded in the United States Patent and Trademark Office at Reel/Frame 025112 / 0178, Reel/Frame 046588 / 0760, Reel/Frame 046588 / 0748 may not fully and concisely set out the intended chain of title and the assignment recorded at Reel/Frame 025112 / 0178 contains an error in the address of Ascendis Pharma A/S;

Now therefore to confirm and insofar as is relevant supplement or supplant the aforementioned assignments, for good and sufficient consideration receipt of which is acknowledged by each assignor;

Inventors Dr. Felix Cleemann, Dr. Ulrich Hersel, Dr. Silvia Kaden-Vagt, Dr. Harald Rau and Dr. Thomas Wegge have assigned and by these presents do assign all their right, title and interest in the application and any invention described therein including any right to claim priority under the Paris convention, US or other law and any patent to issue therefrom, and any continuation, divisional, continuation-in-part, reissue or other application in the US or other country claiming priority thereto and any patent to issue therefrom to Ascendis Pharma GmbH;

Ascendis Pharma GmbH has assigned and by these presents does assign all its right, title and interest in the application and any invention described therein including any right to claim priority under the Paris convention, US or other law and any patent to issue therefrom, and any continuation, divisional, continuation-in-part, reissue or other application in the US or other country claiming priority thereto and any patent to issue therefrom to Ascendis Pharma A/S;

To the extent allowed by law all assignments to be effective at least as of the international filing date of the application indicated above;

SK
03.11.2022
PATENT


Assignment of 12/865,693,
US 8,906,847

The parties authorize Ascendis Pharma A/S's attorneys to correct any matters of form
desirable to give this document effect or permit its recording.

To which the parties have set their hands on the dates indicated;

Dr. Felix Cleemann Date

Dr. Ulrich Hersel Date

 27.07.2022

Dr. Silvia Kaden-Vagt Date

Also known as Dr. Silvia Kaden Initials SK Date 03.11.2022



Dr. Harald Rau Date

Dr. Thomas Wegge Date

Ascendis Pharma GmbH

Signature Date

Print name

Position

Ascendis Pharma A/S

Signature Date

Print name

Position